Clinical Trial Detail

NCT ID NCT01449058
Title A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

myelodysplastic/myeloproliferative neoplasm

Advanced Solid Tumor

acute myeloid leukemia

Therapies

Alpelisib + Binimetinib

Age Groups: adult senior

Additional content available in CKB BOOST